Using the synthetic Tspan24 peptide as a tumor vaccine, the vaccine triggered an active immune response in both primary and metastatic tumor models, promoted tumor CD8 lymphocyte invasion and reduced MDSCs, and effectively inhibited tumor growth and metastasis [75]. This evidence concerns the gene CD8A and neoplasm.